Mizuho raised the firm’s price target on Gilead (GILD) to $100 from $90 and keeps an Outperform rating on the shares. The analyst updated models in the biotechnology group following the Q3 reports. The firm is modeling growth for Gilead’s base HIV business with lenacapavir potentially launching in late 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program
- Gilead price target raised to $100 from $85 at Argus
- Gilead price target raised to $84 from $81 at RBC Capital
- Ideaya Biosciences appoints Stu Dorman as chief commercial officer
- Gilead announces data from interim analysis of Phase 3 ASSURE study